Switching Biological Therapies in Severe Asthma

Currently, three classes of monoclonal antibodies targeting type 2 inflammation pathways are available in Italy for the treatment of severe asthma: anti-IgE (Omalizumab), anti-IL-5/anti-IL-5Rα (Mepolizumab and Benralizumab), and anti-IL-4Rα (Dupilumab). Numerous randomized controlled trials (RCTs) and real-life studies have been conducted to define their efficacy and identify baseline patients’ characteristics potentially predictive of favorable outcomes. Switching to another monoclonal antibody is recommended in case of a lack of benefits. The aim of this work is to review the current knowledge on the impact of switching biological therapies in severe asthma as well as on predictors of treatment response or failure. Almost all of the information about switching from a previous monoclonal antibody to another comes from a real-life setting. In the available studies, the most frequent initial biologic was Omalizumab and patients who were switched because of suboptimal control with a previous biologic therapy were more likely to have a higher baseline blood eosinophil count and exacerbation rate despite OCS dependence. The choice of the most suitable treatment may be guided by the patient’s clinical history, biomarkers of endotype (mainly blood eosinophils and FeNO), and comorbidities (especially nasal polyposis). Due to overlapping eligibility, larger investigations characterizing the clinical profile of patients benefiting from switching to different monoclonal antibodies are needed.

[1]  K. Matsunaga,et al.  A Real-World Study of Achievement Rate and Predictive Factors of Clinical and Deep Remission to Biologics in Patients with Severe Asthma , 2023, Journal of clinical medicine.

[2]  G. Scioscia,et al.  Tezepelumab for asthma. , 2022, Drugs of today.

[3]  G. Canonica,et al.  Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis , 2022, Frontiers in Medicine.

[4]  P. Bardin,et al.  Switching Biological Therapies in Adults with Severe Asthma: What Are the Dilemmas and Is It Worthwhile? , 2022, Annals of the American Thoracic Society.

[5]  D. Murphy,et al.  Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy , 2022, Journal of Asthma and Allergy.

[6]  J. F. Medina Gallardo,et al.  Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma , 2022, Journal of asthma and allergy.

[7]  C. Galeone,et al.  Efficacy and Safety of Omalizumab Treatment Over a 16-Year Follow-Up: When a Clinical Trial Meets Real-Life , 2022, Journal of asthma and allergy.

[8]  K. Kuwano,et al.  Real-World Effectiveness of Dupilumab for Patients with Severe Asthma: A Retrospective Study , 2022, Journal of asthma and allergy.

[9]  O. Resta,et al.  Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management , 2022, Multidisciplinary respiratory medicine.

[10]  C. Porsbjerg,et al.  Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study , 2022, Journal of asthma and allergy.

[11]  Paige Lacy,et al.  Biologics in Asthma: A Molecular Perspective to Precision Medicine , 2022, Frontiers in Pharmacology.

[12]  M. J. Rodríguez-Nieto,et al.  Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study) , 2021, BMC Pulmonary Medicine.

[13]  G. E. Carpagnano,et al.  Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy , 2021, Biomedicines.

[14]  N. Lombardo,et al.  Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis , 2021, Journal of asthma and allergy.

[15]  S. Korn,et al.  Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to Five Years. , 2021, The journal of allergy and clinical immunology. In practice.

[16]  A. Vatrella,et al.  Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma , 2021, Biomedicines.

[17]  F. Haubner,et al.  Hypereosinophilia with systemic manifestations under dupilumab and possibility of dual benralizumab and dupilumab therapy in patients with asthma and CRSwNP. , 2021, The journal of allergy and clinical immunology. In practice.

[18]  R. Intravaia,et al.  Mepolizumab effectiveness in patients with severe eosinophilic asthma and co-presence of bronchiectasis: A real-world retrospective pilot study. , 2021, Respiratory medicine.

[19]  F. Albers,et al.  Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics , 2021, Respiratory Research.

[20]  B. Beghé,et al.  Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program , 2021, Journal of asthma and allergy.

[21]  R. Terracciano,et al.  Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma , 2021, International journal of molecular sciences.

[22]  O. Resta,et al.  Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma , 2021, Scientific Reports.

[23]  E. Bel,et al.  Complications of switching from anti-IL-5 or anti-IL-5R to dupilumab in corticosteroid-dependent severe asthma. , 2021, The journal of allergy and clinical immunology. In practice.

[24]  G. E. Carpagnano,et al.  Effectiveness of Benralizumab in Improving the Quality of Life of Severe Eosinophilic Asthmatic Patients: Our Real-Life Experience , 2021, Frontiers in Pharmacology.

[25]  M. D’Amato,et al.  Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression , 2021, Journal of asthma and allergy.

[26]  M. Triggiani,et al.  Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series , 2021, Journal of asthma and allergy.

[27]  J. Bousquet,et al.  Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. , 2021, The journal of allergy and clinical immunology. In practice.

[28]  A. Nanzer,et al.  Benralizumab after sub‐optimal response to mepolizumab in severe eosinophilic asthma , 2020, Allergy.

[29]  K. Bergmann,et al.  Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma , 2020, Journal of asthma and allergy.

[30]  T. Welte,et al.  Dupilumab improves asthma control and lung function in patients with insufficient outcome during previous antibody therapy. , 2020, The journal of allergy and clinical immunology. In practice.

[31]  R. Intravaia,et al.  Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities , 2020, The World Allergy Organization journal.

[32]  K. Kuwano,et al.  Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study , 2020, BMC Pulmonary Medicine.

[33]  C. Bachert,et al.  Efficacy and safety of omalizumab in nasal polyposis: two randomized phase III trials. , 2020, The Journal of allergy and clinical immunology.

[34]  O. Resta,et al.  Switching from omalizumab to mepolizumab: real-life experience from Southern Italy , 2020, Therapeutic advances in respiratory disease.

[35]  A. Didier,et al.  Effectiveness and safety of dupilumab for the treatment of severe asthma in a real‐life French multi‐centre adult cohort , 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[36]  E. Heffler,et al.  Real‐life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype , 2020, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[37]  F. Albers,et al.  Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sino-nasal and asthma outcomes with mepolizumab therapy. , 2020, The Journal of allergy and clinical immunology.

[38]  A. Murphy,et al.  Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation , 2020 .

[39]  I. Pavord,et al.  Dupilumab Efficacy in Patients With Uncontrolled, Moderate-to-Severe Allergic Asthma. , 2020, The journal of allergy and clinical immunology. In practice.

[40]  B. Modena,et al.  Asthma Biologics: Comparing Trial Designs, Patient Cohorts and Study Results. , 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[41]  A. Murphy,et al.  Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation , 2019, Allergy.

[42]  G. Passalacqua,et al.  Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real‐life observation , 2019, Allergy.

[43]  C. Bachert,et al.  Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials , 2019, The Lancet.

[44]  D. Solé,et al.  Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis. , 2019, Allergologia et immunopathologia.

[45]  R. Terracciano,et al.  Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose. , 2019, Pulmonary pharmacology & therapeutics.

[46]  F. Albers,et al.  The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma , 2019, Allergy.

[47]  H. Ortega,et al.  Assessment of the long‐term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma , 2019, The Journal of allergy and clinical immunology.

[48]  J. Krings,et al.  Role of Biologics in Asthma , 2019, American journal of respiratory and critical care medicine.

[49]  H. Makita,et al.  Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. , 2019, The Lancet. Respiratory medicine.

[50]  A. Arrobas,et al.  Omalizumab for Severe Asthma: Beyond Allergic Asthma , 2018, BioMed research international.

[51]  I. Pavord,et al.  Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.

[52]  K. Rabe,et al.  Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma , 2018, The New England journal of medicine.

[53]  I. Pavord,et al.  Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma , 2018, Advances in Therapy.

[54]  B. Chipps,et al.  Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[55]  K. Matsunaga,et al.  Late-onset asthma: current perspectives , 2018, Journal of asthma and allergy.

[56]  E. Bleecker,et al.  Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. , 2018, The Lancet. Respiratory medicine.

[57]  R. Savino,et al.  Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab , 2017, Drug design, development and therapy.

[58]  P. Silkoff,et al.  Perspectives on exhaled nitric oxide , 2017, Journal of breath research.

[59]  N. Hanania,et al.  Predictive Biomarkers for Asthma Therapy , 2017, Current Allergy and Asthma Reports.

[60]  K. Rabe,et al.  Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma , 2017, The New England journal of medicine.

[61]  F. Albers,et al.  Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. , 2017, The Lancet. Respiratory medicine.

[62]  F. Albers,et al.  Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison. , 2017, Respiratory medicine.

[63]  Á. Cruz,et al.  Revisiting Type 2‐high and Type 2‐low airway inflammation in asthma: current knowledge and therapeutic implications , 2017, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[64]  Zaheer Ul-Haq,et al.  Interleukin-4 receptor signaling and its binding mechanism: A therapeutic insight from inhibitors tool box. , 2016, Cytokine & growth factor reviews.

[65]  E. Bleecker,et al.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.

[66]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[67]  H. Ortega,et al.  Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. , 2016, Clinical therapeutics.

[68]  E. R. Sutherland,et al.  Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial , 2016, The Lancet.

[69]  H. Ortega,et al.  Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment , 2016, Allergy.

[70]  I. Abraham,et al.  ‘Real‐life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review , 2016, Allergy.

[71]  G. Yancopoulos,et al.  Targeting key proximal drivers of type 2 inflammation in disease , 2015, Nature Reviews Drug Discovery.

[72]  Anand A. Dalal,et al.  Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. , 2015, The Journal of allergy and clinical immunology.

[73]  A. Zwinderman,et al.  The prevalence of severe refractory asthma. , 2015, The Journal of allergy and clinical immunology.

[74]  J. Fahy.  Type 2 inflammation in asthma — present in most, absent in many , 2014, Nature Reviews Immunology.

[75]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[76]  I. Pavord,et al.  Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. , 2014, The New England journal of medicine.

[77]  T. Bieber,et al.  Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. , 2014, The New England journal of medicine.

[78]  S. Wenzel,et al.  Dupilumab in persistent asthma with elevated eosinophil levels. , 2013, The New England journal of medicine.

[79]  W. Busse,et al.  Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. , 2013, American journal of respiratory and critical care medicine.

[80]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[81]  W. Busse,et al.  Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. , 2010, Respiratory medicine.

[82]  Parameswaran Nair,et al.  Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. , 2009, The New England journal of medicine.

[83]  Ana Sousa,et al.  Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.

[84]  K. Christopher Garcia,et al.  Molecular and Structural Basis of Cytokine Receptor Pleiotropy in the Interleukin-4/13 System , 2008, Cell.

[85]  W. Busse,et al.  A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. , 2007, American journal of respiratory and critical care medicine.

[86]  J. Bousquet,et al.  Predicting and evaluating response to omalizumab in patients with severe allergic asthma. , 2007, Respiratory medicine.

[87]  Reynold A Panettieri,et al.  Asthma , 1894, Annals of Internal Medicine.

[88]  Klas Svensson,et al.  Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.

[89]  J Bousquet,et al.  Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE , 2005, Allergy.

[90]  J. Bousquet,et al.  Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[91]  H. Renz,et al.  Monoclonal anti-interleukin‐5 treatment suppresses eosinophil but not T‐cell functions , 2003, European Respiratory Journal.

[92]  F. Luscinskas,et al.  Human mast cell progenitors use alpha4-integrin, VCAM-1, and PSGL-1 E-selectin for adhesive interactions with human vascular endothelium under flow conditions. , 2002, Blood.

[93]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[94]  R. Townley,et al.  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. , 2001, The European respiratory journal.

[95]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.